Advertisement

Acquiring Gilead Sciences as a Proposed Strategy for Merck & Co. Growth

  • Derek Haacker
  • Cory Nolan
  • Venkatachalam Seshan
Chapter

Abstract

Merck & Co., a global top ten pharmaceutical company with net sales of $27.4 billion and $13 billion in net income in 2009, controls 4.8 % of the United States market share and 3.39 % of the global pharmaceutical market share (Anon (2011e) Merck 10-K [Online] (Updated 11 February 2011) Available at: http://www.mergentonline.com.lib.pepperdine.edu. Accessed 11 Feb 2011). Through extensive environmental industry analysis and company assessment, the expansion of research and development through the acquisition of biotechnical research Gilead Sciences is a strategy for corporate growth. Gilead is a viable candidate for Merck possessing access to increasingly profitable biotechnology and pipeline presence in the cardiovascular and central nervous market segments. Merck can increase market share and develop new products that reinforce “building and sustaining high performance organizations in a challenging environment.”

Keywords

Market Share Cash Flow Market Segment Central Nervous System Drug Product Pipeline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Acknowledgements include the Wood-Claeyssens Foundation, Pepperdine University, Seaver College, and Lee Kats, Associate Provost for Research at Pepperdine.

References

  1. Anon (2008) Press releases: Gilead [Online] (Updated 01 August 2008) Available at: http://www.gilead.com/pr_1182529. Accessed 12 Feb 2011
  2. Anon (2010) Top corporations by US sales [Online] (Updated July 2010) Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/content/StaticFile/Top_Line_Data/Top%20Corps%2020by%220U.S.Sales.pdf. Accessed 08 Feb 2011
  3. Anon (2011a) Gilead Sciences, Inc. (GILD) [Online] (Updated 11 February 2011) Available at: http://finance.yahoo.com/q?s=GILD. Accesses 11 Feb 2011
  4. Anon (2011b) Corporate history [Online] (Updated January 2011) Available at: http://www.gilead.com/corporate_history. Accessed 08 Feb 2011
  5. Anon (2011c) Gilead Sciences, Inc. 10-K [Online] (Updated 11 February 2011) Available at: http://www.mergentonline.com.lib.pepperdine.edu. Accesses 11 Feb 2011
  6. Anon (2011d) Gilead: products [Online] (Updated January 2011) Available at: http://www.gilead.com/products. Accessed 10 Feb 2011
  7. Anon (2011e) Merck 10-K [Online] (Updated 11 February 2011) Available at: http://www.mergentonline.com.lib.pepperdine.edu. Accessed 11 Feb 2011
  8. Loftlus P (2011) New Pfizer, Merck CEOs take different tacks on research costs [Online] (Updated February 2011) Available at: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=201102031328dowjonesdjonline000414&title=new-pfizermerck-ceos-take-different-tacks-on-research-costs. Accessed 09 Feb 2011
  9. Rowe AJ, Mann RB, Seshan V (2010) Strategy for the 21st century, 5th edn. IBT Global, New YorkGoogle Scholar
  10. Saftlas H (2010) Industry surveys; healthcare: pharmaceuticals [Online] (Updated May 2010) Available at: http://www.netadvantage.standardandpoors.com.lib.pepperdine.edu/NASApp/NetAdvantage/showIndustrySurvey.do?code=hep&date=/hep_0610/hep_0610.htm. Accessed 07 Feb 2011
  11. Seshan V (2010) Strategic management, financial analysis & cash flow, 11th edn. Cengage South-Western. IBT Global, New YorkGoogle Scholar
  12. Sovich N, Mannella N (2011) Sanofi to buy Genzyme for more than $20 billion [Online] (Updated 16 February 2011) Available at: http://www.reuters.com/article/2011/02/16/us-genzyme-sanofi-idUSTRE71E4XI20110216. Accessed 16 Feb 2011

Copyright information

© Springer India 2013

Authors and Affiliations

  • Derek Haacker
    • 1
  • Cory Nolan
    • 1
  • Venkatachalam Seshan
    • 1
  1. 1.Seaver College Business Administration DivisionPepperdine UniversityMalibuUSA

Personalised recommendations